Baird lowers Biogen stock price target to $250 on slow launch product growth
NegativeFinancial Markets

Baird has lowered its price target for Biogen's stock to $250, citing slow growth in the launch of new products. This adjustment reflects concerns about the company's ability to generate momentum in a competitive market, which could impact investor confidence and the overall valuation of Biogen. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of the biotech industry.
— Curated by the World Pulse Now AI Editorial System









